<DOC>
	<DOC>NCT02911857</DOC>
	<brief_summary>The primary objective of this study is to evaluate safety and tolerability of ACZ885 in this extension study. This extension study offers the opportunity for patients who completed Epoch 4 of the preceding CACZ885N2301 study to continue to be treated with ACZ885 until approval in Japan of the drug in Periodic Fever Syndromes or until development of ACZ885 in Periodic Fever Syndromes is suspended.</brief_summary>
	<brief_title>An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Familial Mediterranean Fever</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Completed Epoch 4 of the CACZ885N2301 study in Japan before the approval of canakinumab in Japan Written informed consent. Parent or legal guardian's written informed consent and child's assent, if appropriate, are required before any assessment is performed for patients &lt; 20 years of age Any conditions or significant medical problems in which the investigator judges the patient should not enter this extension study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Canakinumab</keyword>
	<keyword>TRAPS</keyword>
	<keyword>extension study</keyword>
	<keyword>interleukin-1</keyword>
	<keyword>Periodic Fevers Syndrome</keyword>
	<keyword>HIDS</keyword>
	<keyword>crFMF</keyword>
	<keyword>auto-inflammatory diseases</keyword>
</DOC>